CHEBI:167655 - BMS-214662

Main ChEBI Ontology Automatic Xrefs Reactions Pathways Models
ChEBI Name BMS-214662
ChEBI ID CHEBI:167655
Definition A member of the class of benzodiazepines that is 2,3,4,5-tetrahydro-1H-1,4-benzodiazepine substituted by (1H-imidazol-5-yl)methyl, benzyl, (thiophen-2-yl)sulfonyl, and cyano groups at positions 1, 3R, 4 and 7, respectively. It is a potent inhibitor of farnesyltransferase (IC50 = 1.35nM) which was under clinical development for the treatment of solid tumors.
Stars This entity has been manually annotated by the ChEBI Team.
Submitter R. Stephan
Supplier Information
Download Molfile XML SDF
more structures >>
Formula C25H23N5O2S2
Net Charge 0
Average Mass 489.610
Monoisotopic Mass 489.12932
InChI InChI=1S/C25H23N5O2S2/c26-13-20-8-9-24-21(11-20)15-30(34(31,32)25-7-4-10-33-25)23(12-19-5-2-1-3-6-19)17-29(24)16-22-14-27-18-28-22/h1-11,14,18,23H,12,15-17H2,(H,27,28)/t23-/m1/s1
InChIKey OLCWFLWEHWLBTO-HSZRJFAPSA-N
SMILES O=S(=O)(N1CC2=C(C=CC(=C2)C#N)N(CC2=CN=CN2)C[C@H]1CC1=CC=CC=C1)C1=CC=CS1
Roles Classification
Biological Role(s): apoptosis inducer
Any substance that induces the process of apoptosis (programmed cell death) in multi-celled organisms.
EC 2.5.1.58 (protein farnesyltransferase) inhibitor
An EC 2.5.1.* (non-methyl-alkyl or aryl transferase) inhibitor that interferes with the action of protein farnesyltransferase (EC 2.5.1.58), one of the three enzymes in the prenyltransferase group.
GABA modulator
A substance that does not act as agonist or antagonist but does affect the gamma-aminobutyric acid receptor-ionophore complex. GABA-A receptors appear to have at least three allosteric sites at which modulators act: a site at which benzodiazepines act by increasing the opening frequency of gamma-aminobutyric acid-activated chloride channels; a site at which barbiturates act to prolong the duration of channel opening; and a site at which some steroids may act.
(via benzodiazepine )
Application(s): antineoplastic agent
A substance that inhibits or prevents the proliferation of neoplasms.
GABA modulator
A substance that does not act as agonist or antagonist but does affect the gamma-aminobutyric acid receptor-ionophore complex. GABA-A receptors appear to have at least three allosteric sites at which modulators act: a site at which benzodiazepines act by increasing the opening frequency of gamma-aminobutyric acid-activated chloride channels; a site at which barbiturates act to prolong the duration of channel opening; and a site at which some steroids may act.
(via benzodiazepine )
View more via ChEBI Ontology
ChEBI Ontology
Outgoing BMS-214662 (CHEBI:167655) has role antineoplastic agent (CHEBI:35610)
BMS-214662 (CHEBI:167655) has role apoptosis inducer (CHEBI:68495)
BMS-214662 (CHEBI:167655) has role EC 2.5.1.58 (protein farnesyltransferase) inhibitor (CHEBI:64133)
BMS-214662 (CHEBI:167655) is a benzenes (CHEBI:22712)
BMS-214662 (CHEBI:167655) is a benzodiazepine (CHEBI:22720)
BMS-214662 (CHEBI:167655) is a imidazoles (CHEBI:24780)
BMS-214662 (CHEBI:167655) is a nitrile (CHEBI:18379)
BMS-214662 (CHEBI:167655) is a sulfonamide (CHEBI:35358)
BMS-214662 (CHEBI:167655) is a thiophenes (CHEBI:26961)
IUPAC Name
(3R)-3-benzyl-1-(1H-imidazol-5-ylmethyl)-4-(thiophen-2-ylsulfonyl)-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine-7-carbonitrile
Synonyms Sources
(3R)-3-benzyl-1-(1H-imidazol-5-ylmethyl)-4-thiophen-2-ylsulfonyl-3,5-dihydro-2H-1,4-benzodiazepine-7-carbonitrile ChEBI
(R)-2,3,4,5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3-(phenylmethyl)-4-(2-thienylsulfonyl)-1H-1,4-benzodiazepine-7-carbonitrile ChEBI
(R)-7-cyano-2,3,4,5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3-(phenylmethyl)-4-(2-thienylsulfonyl)-1H-1,4-benzodiazepine ChEBI
BMS 214662 ChemIDplus
BMS214662 ChemIDplus
Manual Xrefs Databases
395310 ChemSpider
BMV PDBeChem
DB12234 DrugBank
View more database links
Registry Number Type Source
195987-41-8 CAS Registry Number ChemIDplus
Citations Waiting for Citations Types Sources
11020273 PubMed citation SUBMITTER
11606387 PubMed citation Europe PMC
12789624 PubMed citation Europe PMC
15073096 PubMed citation Europe PMC
15102665 PubMed citation Europe PMC
15170324 PubMed citation Europe PMC
15356656 PubMed citation Europe PMC
15710949 PubMed citation Europe PMC
15728224 PubMed citation Europe PMC
15738311 PubMed citation Europe PMC
15756013 PubMed citation Europe PMC
15930351 PubMed citation Europe PMC
16362299 PubMed citation Europe PMC
17510207 PubMed citation Europe PMC
17956348 PubMed citation Europe PMC
18156496 PubMed citation Europe PMC
19738029 PubMed citation Europe PMC
19883257 PubMed citation Europe PMC
21483442 PubMed citation Europe PMC
23184491 PubMed citation Europe PMC
27688185 PubMed citation Europe PMC
Last Modified
18 March 2021